Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Novo Nordisk (NVO), the maker of the popular GLP-1 medications Wegovy and Ozempic, said potential tariffs ... An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New ...

Ozempic and Rybelsus are marketed by Novo Nordisk for treatment of type 2 diabetes, while Wegovy is marketed for weight loss. Ozempic and Wegovy are both weekly injections. Ozempic is sold in ...

Ozempic and Wegovy come in special injector pens that make it easy to get the dosing right. But the company that makes those drugs, Novo Nordisk, has the exclusive right to make those injector pens.

Ozempic and Wegovy come in special injector pens that make it easy to get the dosing right. But the company that makes those drugs, Novo Nordisk, has the exclusive right to make those injector pens.

As Ozempic and other GLP-1 drugs explode in popularity, driven by their off-label use for rapid weight loss and viral social media trends, the pharmaceutical industry faces unprecedented challenges.

One way is connecting our delivery systems, such as our pens, to your mobile phone ... equity buyouts in Japan's health sector. Novo Nordisk's Ozempic has become the first drug in the GLP-1 ...

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...

Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a ...

Novo Nordisk A/S’s Ozempic helped reduce alcohol cravings in a small study, more evidence that the popular injections may ...

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment. Never before was there a drug that actually worked for weight loss.

Novo Nordisk's 2024 earnings exceeded estimates ... for diabetes treatment continued to show incredible growth. Both Ozempic and Rybelsus grew 26% year-over-year, while Victoza keeps declining ...